Disposition of a murine monoclonal antibody vinca conjugate (KS1/4-DAVLB) in patients with adenocarcinomas. 1990

D Schneck, and F Butler, and W Dugan, and D Littrell, and B Petersen, and R Bowsher, and A DeLong, and S Dorrbecker
Lilly Laboratories for Clinical Research, Eli Lilly Co., Indianapolis, IN.

The pharmacokinetics of a murine monoclonal antibody vinca conjugate (KS1/4-DAVLB) was investigated in 13 patients with adenocarcinomas who received single intravenous doses ranging from 40 to 250 mg/m2 and in three patients who were administered 1.5 mg/kg every 48 to 72 hours for up to 15 doses. Five patients in the single-dose study also received 100 microCi of [3H]-KS1/4-DAVLB. Overall mean values for the pharmacokinetic variables were as follows: elimination half-life, 31.5 hours; distribution volume, 4.43 L; and clearance, 0.09 L/hr. KS1/4-DAVLB demonstrated linear elimination kinetics in both the single- and multiple-dose studies. Significant concentrations of KS1/4-DAVLB were noted in a pleural effusion. Ten percent of the radioactive dose was recovered in the urine and 20% in the feces over a 5-day period. Small molecular weight vinca species were detected in the feces but not in the serum.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008657 Metabolic Clearance Rate Volume of biological fluid completely cleared of drug metabolites as measured in unit time. Elimination occurs as a result of metabolic processes in the kidney, liver, saliva, sweat, intestine, heart, brain, or other site. Total Body Clearance Rate,Clearance Rate, Metabolic,Clearance Rates, Metabolic,Metabolic Clearance Rates,Rate, Metabolic Clearance,Rates, Metabolic Clearance
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012004 Rectal Neoplasms Tumors or cancer of the RECTUM. Cancer of Rectum,Rectal Cancer,Rectal Tumors,Cancer of the Rectum,Neoplasms, Rectal,Rectum Cancer,Rectum Neoplasms,Cancer, Rectal,Cancer, Rectum,Neoplasm, Rectal,Neoplasm, Rectum,Rectal Cancers,Rectal Neoplasm,Rectal Tumor,Rectum Cancers,Rectum Neoplasm,Tumor, Rectal
D003110 Colonic Neoplasms Tumors or cancer of the COLON. Cancer of Colon,Colon Adenocarcinoma,Colon Cancer,Cancer of the Colon,Colon Neoplasms,Colonic Cancer,Neoplasms, Colonic,Adenocarcinoma, Colon,Adenocarcinomas, Colon,Cancer, Colon,Cancer, Colonic,Cancers, Colon,Cancers, Colonic,Colon Adenocarcinomas,Colon Cancers,Colon Neoplasm,Colonic Cancers,Colonic Neoplasm,Neoplasm, Colon,Neoplasm, Colonic,Neoplasms, Colon
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D005434 Flow Cytometry Technique using an instrument system for making, processing, and displaying one or more measurements on individual cells obtained from a cell suspension. Cells are usually stained with one or more fluorescent dyes specific to cell components of interest, e.g., DNA, and fluorescence of each cell is measured as it rapidly transverses the excitation beam (laser or mercury arc lamp). Fluorescence provides a quantitative measure of various biochemical and biophysical properties of the cell, as well as a basis for cell sorting. Other measurable optical parameters include light absorption and light scattering, the latter being applicable to the measurement of cell size, shape, density, granularity, and stain uptake. Cytofluorometry, Flow,Cytometry, Flow,Flow Microfluorimetry,Fluorescence-Activated Cell Sorting,Microfluorometry, Flow,Cell Sorting, Fluorescence-Activated,Cell Sortings, Fluorescence-Activated,Cytofluorometries, Flow,Cytometries, Flow,Flow Cytofluorometries,Flow Cytofluorometry,Flow Cytometries,Flow Microfluorometries,Flow Microfluorometry,Fluorescence Activated Cell Sorting,Fluorescence-Activated Cell Sortings,Microfluorimetry, Flow,Microfluorometries, Flow,Sorting, Fluorescence-Activated Cell,Sortings, Fluorescence-Activated Cell
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes

Related Publications

D Schneck, and F Butler, and W Dugan, and D Littrell, and B Petersen, and R Bowsher, and A DeLong, and S Dorrbecker
October 1991, Pharmaceutical research,
D Schneck, and F Butler, and W Dugan, and D Littrell, and B Petersen, and R Bowsher, and A DeLong, and S Dorrbecker
January 1987, Drug metabolism and disposition: the biological fate of chemicals,
D Schneck, and F Butler, and W Dugan, and D Littrell, and B Petersen, and R Bowsher, and A DeLong, and S Dorrbecker
May 1987, The Journal of pharmacology and experimental therapeutics,
D Schneck, and F Butler, and W Dugan, and D Littrell, and B Petersen, and R Bowsher, and A DeLong, and S Dorrbecker
January 1988, Targeted diagnosis and therapy,
D Schneck, and F Butler, and W Dugan, and D Littrell, and B Petersen, and R Bowsher, and A DeLong, and S Dorrbecker
March 1990, The Journal of pharmacology and experimental therapeutics,
D Schneck, and F Butler, and W Dugan, and D Littrell, and B Petersen, and R Bowsher, and A DeLong, and S Dorrbecker
July 1990, Cancer research,
D Schneck, and F Butler, and W Dugan, and D Littrell, and B Petersen, and R Bowsher, and A DeLong, and S Dorrbecker
June 1990, Cancer research,
D Schneck, and F Butler, and W Dugan, and D Littrell, and B Petersen, and R Bowsher, and A DeLong, and S Dorrbecker
October 1994, American journal of respiratory and critical care medicine,
D Schneck, and F Butler, and W Dugan, and D Littrell, and B Petersen, and R Bowsher, and A DeLong, and S Dorrbecker
August 1990, Cancer research,
D Schneck, and F Butler, and W Dugan, and D Littrell, and B Petersen, and R Bowsher, and A DeLong, and S Dorrbecker
August 1988, Hybridoma,
Copied contents to your clipboard!